Is de-escalation of adjuvant treatment safe in stage I HER2+ tumors larger than 1 cm?
Paolo Tarantino shared on X:
“Is de-escalation of adjuvant treatment safe also in stage I HER2+ tumors larger than 1 cm?
In ATEMPT, patients receiving T-DM1 had excellent 5-year iDFS (>95%) irrespective of tumor size.”
Read further.
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023